Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 10/20 | 0.76 |
| ▸ | TGM1 | P22735 | 4/20 | 0.61 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005365 | 0.89 | F13A1 (0.67) | F13A1TGM1NR3C2KMT2A | |
| SCHEMBL7009658 | 0.89 | F13A1 (0.67) | F13A1TGM1NR3C2KMT2A | |
| SCHEMBL7005641 | 0.87 | F13A1 (0.65) | F13A1TGM1NR3C2KMT2A | |
| SCHEMBL7008678 | 0.86 | F13A1 (1.00) | F13A1TGM1NR3C2 | |
| SCHEMBL7008217 | 0.85 | F13A1 (0.75) | F13A1TGM1KMT2A | |
| SCHEMBL7008810 | 0.84 | F13A1 (0.82) | F13A1TGM1KMT2A | |
| SCHEMBL7007665 | 0.84 | F13A1 (0.71) | F13A1TGM1KMT2ACYP19A1 | |
| SCHEMBL7004923 | 0.83 | F13A1 (0.77) | F13A1TGM1 | |
| SCHEMBL7009337 | 0.82 | F13A1 (0.78) | F13A1TGM1NR3C2 | |
| SCHEMBL7006472 | 0.81 | F13A1 (0.70) | F13A1TGM1MEP1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | APOTEX INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | PIGS, FGB, SERPINE1 | F13A1 14/4885TGM1 7/4885MEP1B 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.